Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Dec;35(4):905-908.
doi: 10.1002/hon.2364. Epub 2016 Oct 13.

Follicular dendritic cell sarcoma treated with a variety of chemotherapy

Masaoki Sasaki  1 , Hiroaki Izumi  2 , Takaaki Yokoyama  1 , Motohiro Kojima  3 , Ako Hosono  1
Affiliations
Case Reports

Follicular dendritic cell sarcoma treated with a variety of chemotherapy

Masaoki Sasaki et al. Hematol Oncol. 2017 Dec.

Abstract

Follicular dendritic cell sarcoma (FDCS) is a very rare malignant tumor derived from follicular dendritic cells. Radical resection is the standard therapy for patients with local disease, but an optimal chemotherapy regimen has not been determined for unresectable disease. We report our experience of an FDCS patient with multiorgan involvement. In the present case, disease was only located in the pancreas initially and radical resection was performed. Multiple metastasis developed after the treatment and several factors that indicated a poor prognosis were observed. The present case had a very poor prognostic disease but survived for a long time with a good performance status because of the multiple chemotherapy regimens, which follow therapeutic strategies for malignant lymphoma and soft tissue sarcoma. As far as we know, this is the first study reporting the indication of bendamustine for FDCS patients.

Keywords: bendamustine; chemotherapy; follicular dendritic cell sarcoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hematoxylin and eosin staining and immunochemical features of the tumor
Figure 2
Figure 2
CT images of abdomen. A, Before DXR. B, After DXR
Figure 3
Figure 3
Relationship between changes in laboratory data (CRP and ALP) and tumor responses to chemotherapy
See this image and copyright information in PMC

References

    1. Saygin C, Uzunaslan D, Ozguroglu M, et al. Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series. Crit Rev Oncol Hematol. 2013;88(2):253–271. - PubMed
    1. Dalia S, Shao H, Sagatys E, et al. Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control. 2014;21(4):290–300. - PubMed
    1. Dalia S, Jaglal M, Chervenick P, et al. Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty five years. Cancers. 2014;6(4):2275–2295. - PMC - PubMed
    1. Caces DB, Daniel S, Paredes‐Tejada JM, et al. Spontaneous regression of follicular dendritic cell sarcoma. J Clin Oncol. 2012;30(3):e24–e26. - PubMed
    1. Perkins SM, Shinohara ET. Interdigitating and follicular dendritic cell sarcomas: a SEER analysis. Am J Clin Oncol. 2013;36(4):395–398. - PubMed

Publication types